Truist Financial Has Lowered Expectations for Amrize (NYSE:AMRZ) Stock Price

Amrize (NYSE:AMRZ) had its price objective cut by investment analysts at Truist Financial from $48.00 to $35.00 in a research note issued on Monday, MarketBeat reports. The brokerage presently has a “hold” rating on the stock. Truist Financial’s target price suggests a potential downside of 6.09% from the company’s previous close.

Several other brokerages have also weighed in on AMRZ. Sanford C. Bernstein reiterated an “outperform” rating and set a $60.00 target price on shares of Amrize in a research report on Monday, September 21st. JPMorgan Chase & Co. cut shares of Amrize from an “overweight” rating to a “neutral” rating and cut their price target for the stock from $57.00 to $52.00 in a research note on Wednesday, September 2nd. UBS Group decreased their price objective on Amrize from $57.00 to $42.00 and set a “neutral” rating on the stock in a report on Tuesday, September 22nd. Bank of America reiterated an “underperform” rating and issued a $40.00 price objective (down from $50.00) on shares of Amrize in a research note on Wednesday, September 2nd. Finally, Deutsche Bank Aktiengesellschaft dropped their target price on Amrize from $64.00 to $56.00 and set a “buy” rating for the company in a report on Wednesday, September 23rd. One equities research analyst has rated the stock with a Strong Buy rating, seven have issued a Buy rating, eight have given a Hold rating and three have given a Sell rating to the stock. According to data from MarketBeat, the stock currently has a consensus rating of “Hold” and a consensus price target of $51.76.

Amrize Stock Performance

Shares of NYSE AMRZ opened at $37.27 on Monday. The business has a fifty day simple moving average of $43.12 and a 200 day simple moving average of $49.81. The company has a current ratio of 1.10, a quick ratio of 0.73 and a debt-to-equity ratio of 0.33. The firm has a market capitalization of $20.61 billion, a price-to-earnings ratio of 17.18, a PEG ratio of 1.31 and a beta of 0.20. Amrize has a one year low of $36.55 and a one year high of $65.94.

Amrize (NYSE:AMRZ) last issued its earnings results on Thursday, August 6th. The company reported $0.88 EPS for the quarter, missing the consensus estimate of $0.92 by ($0.04). The firm had revenue of $3.49 billion during the quarter. Amrize had a return on equity of 10.22% and a net margin of 9.89%. Sell-side analysts expect that Amrize will post 2.46 EPS for the current year.

Insider Activity at Amrize

In other Amrize news, insider Stephen Clark bought 5,260 shares of the business’s stock in a transaction on Tuesday, August 11th. The shares were bought at an average cost of $47.31 per share, for a total transaction of $248,850.60. Following the transaction, the insider owned 10,637 shares in the company, valued at approximately $503,236.47. This trade represents a 97.82% increase in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this link. Also, CEO Jan Jenisch bought 26,000 shares of Amrize stock in a transaction dated Wednesday, September 2nd. The stock was acquired at an average cost of $42.47 per share, for a total transaction of $1,104,220.00. Following the purchase, the chief executive officer directly owned 1,767,000 shares in the company, valued at approximately $75,044,490. The trade was a 1.49% increase in their position. The disclosure for this purchase is available in the SEC filing. In the last quarter, insiders acquired 48,983 shares of company stock worth $2,158,755. Insiders own 0.54% of the company’s stock.

Institutional Trading of Amrize

A number of institutional investors have recently bought and sold shares of AMRZ. MCF Advisors LLC acquired a new position in shares of Amrize in the 4th quarter valued at $27,000. Continuum Advisory LLC acquired a new stake in shares of Amrize during the second quarter worth $62,000. NewEdge Advisors LLC grew its stake in shares of Amrize by 1,419.7% during the second quarter. NewEdge Advisors LLC now owns 2,082 shares of the company’s stock worth $111,000 after purchasing an additional 1,945 shares during the period. Oslo Pensjonsforsikring AS bought a new stake in Amrize in the first quarter valued at about $133,000. Finally, Caldwell Sutter Capital Inc. increased its holdings in Amrize by 11.5% in the first quarter. Caldwell Sutter Capital Inc. now owns 2,675 shares of the company’s stock valued at $150,000 after purchasing an additional 275 shares during the last quarter.

Amrize Company Profile

Amrize Ltd. is a North American building solutions company that produces and supplies essential construction materials and related products. Its portfolio includes cement, aggregates, ready-mix concrete, asphalt, concrete products and roofing systems used in residential, commercial and infrastructure projects.

The company serves customers across the United States and Canada through a network of production facilities, distribution locations and other operating sites. Its products support a range of construction applications, including roads, bridges, buildings, homes and other major infrastructure.

Amrize was established as the result of the separation of Holcim’s North American business and began operating as an independent, publicly traded company in 2025.